Depressive Illnesses: Ketamine
The question
To ask the Secretary of State for Health and Social Care, whether he plans to request that NICE conduct an exceptional (expedited) partial review of the NICE Depression guideline (NG222) to consider the inclusion of intravenous racemic ketamine as an option for patients for whom electroconvulsive therapy is being considered.
Answered by Dr Zubir Ahmed
The Department has no plans to ask the National Institute for Health and Care Excellence (NICE) to conduct a review of the NICE guideline on the treatment and management of depression, reference code NG222.
NICE is an independent body and is responsible for taking decisions on whether its guidelines should be updated in light of new evidence and changes in clinical practice. NICE operates an active surveillance programme and when new evidence emerges, it proactively considers whether existing guidance should be reviewed and, if appropriate, updated. Decisions as to whether NICE will create new, or update existing, guidance are overseen by an integrated, cross-organisational prioritisation board. NICE has no current plans to review intravenous racemic ketamine in the context of the depression guideline.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →